SQLite Web: event_store.db

Update row sig_a5f2b12096f8 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","as_of":"2026-04-10T17:21:18.772571+00:00","canonical_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","article_chars":3827,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_61819ccfd1f1ecdb","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-11T22:00:43.675658+00:00","extraction_method":"trafilatura","fetched_description":"Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.","fetched_title":"KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 | Nasdaq","final_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","source_event_id":"evt_5288c6e412a5","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"fffae612a44a87bf","kind":"new_listings","published_at":"2026-04-10T16:04:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["June 2025","2027"],"entities":[{"asset_class":"equity","name":"Kymera Therapeutics","relevance":"high","symbol":"KYMR","type":"company"},{"asset_class":"equity","name":"Gilead Sciences","relevance":"high","symbol":"GILD","type":"company"},{"asset_class":"biotech_program","name":"KT-200","relevance":"high","symbol":"","type":"product_program"},{"asset_class":"biotech_target","name":"CDK2","relevance":"medium","symbol":"","type":"target"}],"event_type":"listing","information_gaps":["The signal type is labeled as discovery_new_listings_delta, but the provided text describes a licensing/milestone event rather than a new listing; the mapping to 'new listings' is not evidenced in the text.","The article does not specify the exact date of the $45 million milestone payment trigger beyond 'has exercised its option.'","No details are provided on the specific milestone criteria met for the $45 million payment (e.g., which development/regulatory step).","No explicit confirmation is provided of whether the $45 million is already received versus only entitled/expected."],"key_facts":["Gilead exercised its option to obtain an exclusive license for Kymera\u2019s KT-200 under a strategic collaboration agreement.","Kymera is entitled to a $45 million milestone payment.","In June 2025, Kymera entered an exclusive option and license agreement with Gilead for a CDK2 molecular glue degrader program (KT-200).","Under the agreement, Kymera is eligible to receive up to $750 million in total payments contingent on development, regulatory, and commercial milestones.","Kymera has already realized $85 million in upfront and option exercise payments.","Kymera is eligible for tiered royalties on net product sales ranging from the high single digits to the mid-teens.","Kymera leads all research activities for the CDK2 program; Gilead retains global rights to develop, manufacture, and commercialize products from the collaboration.","KT-200 is described as an oral cyclin-dependent kinase 2 (CDK2) molecular glue degrader (MGD).","The article states KT-200 demonstrated low-nanomolar CDK2 degradation, strong activity in CCNE1-driven models, potential brain penetration, and a favorable safety profile in preclinical studies.","The article states Gilead plans to advance KT-200 into IND-enabling studies with a goal of supporting an IND filing in 2027.","The article states Kymera\u2019s shares have rallied 12.3% year to date versus the industry\u2019s 2.1% growth."],"numeric_claims":[{"label":"milestone_payment_usd","value":"45 million"},{"label":"total_contingent_payments_usd","value":"up to 750 million"},{"label":"upfront_and_option_exercise_payments_usd","value":"85 million"},{"label":"royalty_range","value":"high single digits to mid-teens"},{"label":"share_performance_ytd","value":"12.3%"},{"label":"industry_growth_ytd","value":"2.1%"}],"primary_claim":"Gilead exercised its option for an exclusive license to Kymera\u2019s KT-200 and Kymera is entitled to a $45 million milestone payment.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Kymera Therapeutics (KYMR) said Gilead Sciences (GILD) exercised an option to obtain an exclusive license for KT-200 and that Kymera is entitled to a $45 million milestone payment. The companies\u2019 collaboration also provides for up to $750 million in total contingent payments and tiered royalties on net product sales.","topics":["biotech licensing","molecular glue degrader","CDK2","milestone payment","Gilead-Kymera collaboration","oncology development"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.","tickers":[],"title":"KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200","url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel